1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Biomarker Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Lung Cancer
1.2.3 Breast Cancer
1.2.4 Colorectal Cancer
1.2.5 Prostate Cancer
1.2.6 Stomach Cancer
1.2.7 Others
1.3 Market by Application
1.3.1 Global Oncology Biomarker Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Diagnostics
1.3.3 Drug Discovery And Development
1.3.4 Prognostics
1.3.5 Risk Assessment
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Oncology Biomarker Market Perspective (2017-2028)
2.2 Oncology Biomarker Growth Trends by Region
2.2.1 Oncology Biomarker Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Oncology Biomarker Historic Market Size by Region (2017-2022)
2.2.3 Oncology Biomarker Forecasted Market Size by Region (2023-2028)
2.3 Oncology Biomarker Market Dynamics
2.3.1 Oncology Biomarker Industry Trends
2.3.2 Oncology Biomarker Market Drivers
2.3.3 Oncology Biomarker Market Challenges
2.3.4 Oncology Biomarker Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Oncology Biomarker Players by Revenue
3.1.1 Global Top Oncology Biomarker Players by Revenue (2017-2022)
3.1.2 Global Oncology Biomarker Revenue Market Share by Players (2017-2022)
3.2 Global Oncology Biomarker Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Biomarker Revenue
3.4 Global Oncology Biomarker Market Concentration Ratio
3.4.1 Global Oncology Biomarker Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Biomarker Revenue in 2021
3.5 Oncology Biomarker Key Players Head office and Area Served
3.6 Key Players Oncology Biomarker Product Solution and Service
3.7 Date of Enter into Oncology Biomarker Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Oncology Biomarker Breakdown Data by Type
4.1 Global Oncology Biomarker Historic Market Size by Type (2017-2022)
4.2 Global Oncology Biomarker Forecasted Market Size by Type (2023-2028) 5 Oncology Biomarker Breakdown Data by Application
5.1 Global Oncology Biomarker Historic Market Size by Application (2017-2022)
5.2 Global Oncology Biomarker Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Oncology Biomarker Market Size (2017-2028)
6.2 North America Oncology Biomarker Market Size by Type
6.2.1 North America Oncology Biomarker Market Size by Type (2017-2022)
6.2.2 North America Oncology Biomarker Market Size by Type (2023-2028)
6.2.3 North America Oncology Biomarker Market Share by Type (2017-2028)
6.3 North America Oncology Biomarker Market Size by Application
6.3.1 North America Oncology Biomarker Market Size by Application (2017-2022)
6.3.2 North America Oncology Biomarker Market Size by Application (2023-2028)
6.3.3 North America Oncology Biomarker Market Share by Application (2017-2028)
6.4 North America Oncology Biomarker Market Size by Country
6.4.1 North America Oncology Biomarker Market Size by Country (2017-2022)
6.4.2 North America Oncology Biomarker Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada 7 Europe
7.1 Europe Oncology Biomarker Market Size (2017-2028)
7.2 Europe Oncology Biomarker Market Size by Type
7.2.1 Europe Oncology Biomarker Market Size by Type (2017-2022)
7.2.2 Europe Oncology Biomarker Market Size by Type (2023-2028)
7.2.3 Europe Oncology Biomarker Market Share by Type (2017-2028)
7.3 Europe Oncology Biomarker Market Size by Application
7.3.1 Europe Oncology Biomarker Market Size by Application (2017-2022)
7.3.2 Europe Oncology Biomarker Market Size by Application (2023-2028)
7.3.3 Europe Oncology Biomarker Market Share by Application (2017-2028)
7.4 Europe Oncology Biomarker Market Size by Country
7.4.1 Europe Oncology Biomarker Market Size by Country (2017-2022)
7.4.2 Europe Oncology Biomarker Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Oncology Biomarker Market Size (2017-2028)
8.2 Asia-Pacific Oncology Biomarker Market Size by Type
8.2.1 Asia-Pacific Oncology Biomarker Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Oncology Biomarker Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Oncology Biomarker Market Share by Type (2017-2028)
8.3 Asia-Pacific Oncology Biomarker Market Size by Application
8.3.1 Asia-Pacific Oncology Biomarker Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Oncology Biomarker Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Oncology Biomarker Market Share by Application (2017-2028)
8.4 Asia-Pacific Oncology Biomarker Market Size by Region
8.4.1 Asia-Pacific Oncology Biomarker Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Oncology Biomarker Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia 9 Latin America
9.1 Latin America Oncology Biomarker Market Size (2017-2028)
9.2 Latin America Oncology Biomarker Market Size by Type
9.2.1 Latin America Oncology Biomarker Market Size by Type (2017-2022)
9.2.2 Latin America Oncology Biomarker Market Size by Type (2023-2028)
9.2.3 Latin America Oncology Biomarker Market Share by Type (2017-2028)
9.3 Latin America Oncology Biomarker Market Size by Application
9.3.1 Latin America Oncology Biomarker Market Size by Application (2017-2022)
9.3.2 Latin America Oncology Biomarker Market Size by Application (2023-2028)
9.3.3 Latin America Oncology Biomarker Market Share by Application (2017-2028)
9.4 Latin America Oncology Biomarker Market Size by Country
9.4.1 Latin America Oncology Biomarker Market Size by Country (2017-2022)
9.4.2 Latin America Oncology Biomarker Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Oncology Biomarker Market Size (2017-2028)
10.2 Middle East & Africa Oncology Biomarker Market Size by Type
10.2.1 Middle East & Africa Oncology Biomarker Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Oncology Biomarker Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Oncology Biomarker Market Share by Type (2017-2028)
10.3 Middle East & Africa Oncology Biomarker Market Size by Application
10.3.1 Middle East & Africa Oncology Biomarker Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Oncology Biomarker Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Oncology Biomarker Market Share by Application (2017-2028)
10.4 Middle East & Africa Oncology Biomarker Market Size by Country
10.4.1 Middle East & Africa Oncology Biomarker Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Oncology Biomarker Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE 11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Oncology Biomarker Introduction
11.1.4 Abbott Laboratories Revenue in Oncology Biomarker Business (2017-2022)
11.1.5 Abbott Laboratories Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Oncology Biomarker Introduction
11.2.4 Bristol-Myers Squibb Revenue in Oncology Biomarker Business (2017-2022)
11.2.5 Bristol-Myers Squibb Recent Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Details
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Oncology Biomarker Introduction
11.3.4 Eli Lilly and Company Revenue in Oncology Biomarker Business (2017-2022)
11.3.5 Eli Lilly and Company Recent Developments
11.4 F.Hoffmann-La Roche Ltd.
11.4.1 F.Hoffmann-La Roche Ltd. Company Details
11.4.2 F.Hoffmann-La Roche Ltd. Business Overview
11.4.3 F.Hoffmann-La Roche Ltd. Oncology Biomarker Introduction
11.4.4 F.Hoffmann-La Roche Ltd. Revenue in Oncology Biomarker Business (2017-2022)
11.4.5 F.Hoffmann-La Roche Ltd. Recent Developments
11.5 Genomic Health
11.5.1 Genomic Health Company Details
11.5.2 Genomic Health Business Overview
11.5.3 Genomic Health Oncology Biomarker Introduction
11.5.4 Genomic Health Revenue in Oncology Biomarker Business (2017-2022)
11.5.5 Genomic Health Recent Developments
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Details
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Oncology Biomarker Introduction
11.6.4 GlaxoSmithKline plc Revenue in Oncology Biomarker Business (2017-2022)
11.6.5 GlaxoSmithKline plc Recent Developments
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Oncology Biomarker Introduction
11.7.4 Novartis AG Revenue in Oncology Biomarker Business (2017-2022)
11.7.5 Novartis AG Recent Developments
11.8 Merck & Co.
11.8.1 Merck & Co. Company Details
11.8.2 Merck & Co. Business Overview
11.8.3 Merck & Co. Oncology Biomarker Introduction
11.8.4 Merck & Co. Revenue in Oncology Biomarker Business (2017-2022)
11.8.5 Merck & Co. Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Oncology Biomarker Introduction
11.9.4 Pfizer Revenue in Oncology Biomarker Business (2017-2022)
11.9.5 Pfizer Recent Developments
11.10 Qiagen N.V.
11.10.1 Qiagen N.V. Company Details
11.10.2 Qiagen N.V. Business Overview
11.10.3 Qiagen N.V. Oncology Biomarker Introduction
11.10.4 Qiagen N.V. Revenue in Oncology Biomarker Business (2017-2022)
11.10.5 Qiagen N.V. Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
